Why the study?
Restoring parasympathetic activity is a promising approach for cardiovascular diseases, but vagal nerve stimulation has been unsuccessful in heart failure.
Do novel chemogenetic approaches to activate the vagal pathway provide cardioprotection in heart failure and obstructive sleep apnea?
Do novel chemogenetic approaches to activate the vagal pathway provide cardioprotection in heart failure and obstructive sleep apnea?
Answers are grounded in this paper and cite their sources.
Chemogenetic activation of the vagal pathway represents a novel, potentially selective therapeutic approach for restoring parasympathetic activity in heart failure and obstructive sleep apnea.
Neural control of the heart is regulated by sympathetic and parasympathetic divisions of the autonomic nervous system, both opposing each other to maintain cardiac homeostasis via regulating heart rate, conduction velocity, force of contraction, and coronary blood flow. Sympathetic hyperactivity and diminished parasympathetic activity are the characteristic features of many cardiovascular disease states including hypertension, myocardial ischemia, and arrhythmias that result in heart failure. Restoring parasympathetic activity to the heart has recently been identified as the promising approach to treat such conditions. However, approaches that used vagal nerve stimulation have been shown to be unsuccessful in heart failure. This review focuses on novel chemogenetic approaches used to identify the cardioprotective nature of activating neural points along the vagal pathway (both central and peripheral) while being selectively therapeutic in heart failure and obstructive sleep apnea.
No takes yet. Share an insight, caveat, or question.
Jhansi Dyavanapalli (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: